India-based Cipla has plans to explore the use of multi-drug combination, including Gilead Sciences’ investigational antiviral drug remdesivir, for the treatment of Covid-19 coronavirus infection.
In an interview with Livemint news agency, Cipla chief financial officer Kedar Upadhye said that the company intends to assess a combination of zinc, hydroxychloroquine, azithromycin, lopinavir-ritonavir and favipiravir, among other drugs.
Upadhye was quoted as saying: “We are trying all avenues. We are attempting to come to the service of patients and try to see which molecule is more effective.
We are trying through all ways. I think we will attack Covid-19 through multiple ways.” Cipla is among the five companies that entered a non-exclusive